Actavis reveals post-merger management plans: Saunders to stay as CEO
- Since Actavis reached its $66 billion acquisition deal with Allergan last month, the companies have been merging operations and solidifying structure. Although current Actavis CEO Brent Saunders will maintain his position as CEO, the management team will include members of both Actavis's and Allergan's executive ranks.
- The combined Actavis-Allergan company with have a global brand sales and marketing team based on a three-organization structure comprised of international brands, branded pharma, and Allergan Pharma, according to the WSJ.
- Actavis has estimated that it has roughly 24 to 36 near-term products in development.
The consensus is that the merger is going fairly smoothly, although like any merger, there is some collateral damage.
As Brent Saunders consolidates operations, he says he is committed to cutting "layers of bureaucracy," as well as jobs and research programs that the management team deems redundant or unnecessary, with the goal of at least $1.8 billion in cuts.